These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 29697418

  • 1. Recent progress in systemic treatment for lung cancer.
    Clark JW, Longo DL.
    Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
    [Abstract] [Full Text] [Related]

  • 2. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
    Lambros L, Guibourg B, Uguen A.
    Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
    [No Abstract] [Full Text] [Related]

  • 3. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 4. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
    Daga A, Ansari A, Patel S, Mirza S, Rawal R, Umrania V.
    Asian Pac J Cancer Prev; 2015 Dec; 16(10):4147-56. PubMed ID: 26028064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L, Xu M, Jiang X, Sun X.
    Med Sci Monit; 2018 Dec 23; 24():9364-9369. PubMed ID: 30580372
    [Abstract] [Full Text] [Related]

  • 11. Treatment of older patients with advanced non-small cell lung cancer: A challenge.
    Decoster L, Schallier D.
    J Geriatr Oncol; 2019 Jul 23; 10(4):528-533. PubMed ID: 30301660
    [Abstract] [Full Text] [Related]

  • 12. Personalized therapy for lung cancer: striking a moving target.
    Pakkala S, Ramalingam SS.
    JCI Insight; 2018 Aug 09; 3(15):. PubMed ID: 30089719
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY.
    J Thorac Oncol; 2016 Jul 09; 11(7):1140-52. PubMed ID: 27094798
    [Abstract] [Full Text] [Related]

  • 14. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K.
    J Natl Cancer Inst; 2010 May 19; 102(10):672-5. PubMed ID: 20460631
    [No Abstract] [Full Text] [Related]

  • 15. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J, Hendriks LE, Cabrera C, Reguart N, Besse B.
    Cancer Treat Rev; 2018 Dec 19; 71():47-58. PubMed ID: 30359792
    [Abstract] [Full Text] [Related]

  • 16. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 19; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 17. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 18. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
    Rosell R, Karachaliou N, Wolf J, Ou SH.
    Lancet Respir Med; 2014 Dec 15; 2(12):966-8. PubMed ID: 25466349
    [No Abstract] [Full Text] [Related]

  • 19. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 Dec 15; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

  • 20. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 15; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.